Penumbra completes enrolment for THUNDER study to treat ischemic stroke

The Penumbra System with Thunderbolt Aspiration Tubing leverages a CAVT software algorithm. Credit: Explode via Shutterstock. · Medical Device Network · Explode via Shutterstock.

In This Article:

US-based Penumbra has completed enrolment for the THUNDER Investigational Device Exemption study of its advanced thrombectomy technology for acute ischemic stroke treatment.

This study will evaluate the safety and efficacy of the Penumbra System with Thunderbolt Aspiration Tubing, for blood clot removal in the brain.

The single-arm, multicentre trial targets patients with acute ischemic stroke caused by intracranial large vessel occlusion (LVO).

The primary efficacy endpoint of the study is the immediate post-procedure revascularisation of the occluded target vessel.

The Penumbra System with Thunderbolt Aspiration Tubing leverages a computer-assisted vacuum thrombectomy (CAVT) software algorithm.

This algorithm produces modulated aspiration, which minimises friction between the clot and the reperfusion catheter.

Consequently, it facilitates a swifter and more thorough removal of clots.

Thunderbolt Aspiration Tubing is specifically designed to be compatible with the Penumbra ENGINE and RED reperfusion catheters.

Penumbra president and CEO Adam Elsesser said: “This critical milestone brings us another step closer to providing physicians with the latest technology for stroke management.

“The THUNDER study will provide the data set needed to evaluate Penumbra’s Thunderbolt technology and I am optimistic that we are at the dawn of a new era in stroke treatment.”

In April this year, Penumbra secured US Food and Drug Administration approval and launched Lightning Flash 2.0, a next-generation CAVT system.

Featuring advanced algorithms for increased speed and sensitivity during clot removal, the Lightning Flash 2.0 system is intended for the removal of venous thrombus and treats pulmonary emboli.

"Penumbra completes enrolment for THUNDER study to treat ischemic stroke" was originally created and published by Medical Device Network, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.